Occurrence and Risk of Cochleotoxicity in Cystic Fibrosis Patients Receiving Repeated High-Dose Aminoglycoside Therapy
Open Access
- 1 September 2001
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 45 (9), 2502-2509
- https://doi.org/10.1128/aac.45.9.2502-2509.2001
Abstract
Cystic fibrosis (CF) patients receive repeated courses of aminoglycoside therapy. These patients would consequently be expected to be more susceptible to cochleotoxicity, a recognized side effect with single courses of aminoglycoside therapy. The primary aim of this retrospective study was to establish the incidence and severity of auditory deficit in CF patients. Standard (0.25- to 8-kHz) and high-frequency (10- to 16-kHz) pure-tone audiometry was carried out in 70 CF patients, and the results were compared with the results from 91 control subjects. These subjects were further divided into pediatric and adult groups. Of 70 CF patients, 12 (1 pediatric) displayed hearing loss considered to be caused by repeated exposure to aminoglycosides. There was a nonlinear relationship between the courses of therapy received and the incidence of hearing loss. The severity of the loss did not appear to be related to the number of courses received. Assuming the risk of loss to be independent for each course, preliminary estimates of per course risk of hearing loss were less than 2%. Upon comparison with previous clinical studies and experimental work, these findings suggest that the incidence of cochleotoxicity in CF patients is considerably lower than would be expected, suggesting that the CF condition may confer protection against aminoglycoside cochleotoxicity.This publication has 40 references indexed in Scilit:
- Improving Audiometric Thresholds by Changing the Headphone Position at the EarInternational Journal of Audiology, 1995
- Recommended procedure for tympanometry: British Society of AudiologyBritish Journal of Audiology, 1992
- Threshold of hearing as a function of age and sex for the typical unscreened populationBritish Journal of Audiology, 1988
- Antibiotic Pharmacokinetics in Cystic FibrosisClinical Pharmacokinetics, 1987
- Intensive Treatment of Pseudomonas Chest Infection in Cystic Fibrosis: a Comparison of Tobramycin and Ticarcillin, and Netilmicin and TicarcillinActa Paediatrica, 1985
- Recommended procedure for pure-tone bone-conduction audiometry without masking using a manually operated instrumentBritish Journal of Audiology, 1985
- Drug-induced OtotoxicityDrugs, 1980
- Ototoxicity of Tobramycin: A Clinical OverviewThe Journal of Infectious Diseases, 1976
- Tobramycin Therapy of Infections Due to Pseudomonas aeruginosa in Patients with Cystic Fibrosis: Effect of Dosage and Concentration of Antibiotic in SputumThe Journal of Infectious Diseases, 1976
- Ototoxicity of Gentamicin in Man: A Survey and Controlled Analysis of Clinical Experience in the United StatesThe Journal of Infectious Diseases, 1971